CONNECTING BREAKTHROUGH IDEAS WITH GROUNDBREAKING RESULTS

CONNECTING BREAKTHROUGH IDEAS WITH GROUNDBREAKING RESULTS

Robert Whitehead – Chief Executive Officer & Director

Robert Whitehead serves as the Chief Executive Officer of our Company and is a member of our Board of Directors. Mr. Whitehead was the co-founder and served as Chief Executive Officer of Sprout Pharmaceuticals, a biopharmaceutical company from 2011to 2014. He served as Chief Operating Officer from 2014 until the Company was sold to Valeant in 2015 for more than $2.5 billion in total upfront and contingent consideration. He led the reacquisition of Sprout in 2017 and currently serves as a member of Sprout’s Board of Directors. Founded in 2011, Sprout obtained the approval of Addyi, the first and only oral approved treatment for hypoactive sexual desire disorder in premenopausal women. The product is marketed today in the United States and Canada.

Prior to founding Sprout Pharmaceuticals, Mr. Whitehead co-founded and served as Chief Executive Officer and a director of Slate Pharmaceuticals until Slate’s acquisition by Actient/GTCR in December 2011 for $150 million in total consideration. Prior executive positions include President and Chief Operating Officer of Auxilium Pharmaceuticals, Inc., a publicly traded specialty pharmaceutical company in the fields of urology and men’s health (Auxilium sold to Endo Pharmaceuticals in 2014 for $2.2 billion); Chief Executive Officer of Prestwick Pharmaceuticals, Inc., a specialty pharmaceutical company (acquired by Biovail for $100 million in 2008), Chief Business Officer of ZymoGenetics, Inc., a biopharmaceutical company (acquired by Bristol Myers Squibb for $885 million in 2010); and Chief Operating Officer of Dura Pharmaceuticals and Élan Pharmaceuticals, Inc., which acquired Dura Pharmaceuticals in 2000 for $2 billion.

Mr. Whitehead’s investment and capital management expertise includes experience as an early-stage investor, board member and/or advisor to multiple national and international start-up healthcare firms including Lia, IntuiTap, Juno, Renovia, uMethod and several others. We believe Mr. Whitehead is well qualified to serve as a member of our Board of Directors due to his extensive healthcare experience, private and public company experience, and executive leadership skills.

Robert Whitehead – Chief Executive Officer & Director

Robert Whitehead serves as the Chief Executive Officer of our Company and is a member of our Board of Directors. Mr. Whitehead was the co-founder and served as Chief Executive Officer of Sprout Pharmaceuticals, a biopharmaceutical company from 2011to 2014. He served as Chief Operating Officer from 2014 until the Company was sold to Valeant in 2015 for more than $2.5 billion in total upfront and contingent consideration. He led the reacquisition of Sprout in 2017 and currently serves as a member of Sprout’s Board of Directors. Founded in 2011, Sprout obtained the approval of Addyi, the first and only oral approved treatment for hypoactive sexual desire disorder in premenopausal women. The product is marketed today in the United States and Canada.

Prior to founding Sprout Pharmaceuticals, Mr. Whitehead co-founded and served as Chief Executive Officer and a director of Slate Pharmaceuticals until Slate’s acquisition by Actient/GTCR in December 2011 for $150 million in total consideration. Prior executive positions include President and Chief Operating Officer of Auxilium Pharmaceuticals, Inc., a publicly traded specialty pharmaceutical company in the fields of urology and men’s health (Auxilium sold to Endo Pharmaceuticals in 2014 for $2.2 billion); Chief Executive Officer of Prestwick Pharmaceuticals, Inc., a specialty pharmaceutical company (acquired by Biovail for $100 million in 2008), Chief Business Officer of ZymoGenetics, Inc., a biopharmaceutical company (acquired by Bristol Myers Squibb for $885 million in 2010); and Chief Operating Officer of Dura Pharmaceuticals and Élan Pharmaceuticals, Inc., which acquired Dura Pharmaceuticals in 2000 for $2 billion.

Mr. Whitehead’s investment and capital management expertise includes experience as an early-stage investor, board member and/or advisor to multiple national and international start-up healthcare firms including Lia, IntuiTap, Juno, Renovia, uMethod and several others. We believe Mr. Whitehead is well qualified to serve as a member of our Board of Directors due to his extensive healthcare experience, private and public company experience, and executive leadership skills.

360 Central Avenue
First Central Tower
Suite #800
St. Petersburg, Florida 33701
(727) 245-0146.